

## Translating Evidence into Practice

**DAY 1** (Saturday, 14th March 2020)

- 08:00 - 08:20 **Opening Address**  
**REBECCA DENT**, Singapore / **SHAHEENAH DAWOOD**, UAE
- 
- 08:20 - 09:20 **Breakfast Satellite Symposium Sponsored by Roche**  
 Multi-disciplinary perspectives on optimizing patient outcomes in HER2- Positive and triple-negative breast cancer  
 Chairperson: **KHOO KEI SIONG**, Singapore  
 Panel: **HENRY CAIN**, UK / **HOPE RUGO**, USA / **TBA**

### PLENARY SESSION 1: Translational Breast Cancer Done Right!

Chairpersons: **BENITA TAN**, Singapore / **TAM WAI LEONG**, Singapore

- 09:20 - 09:40 **Applying 2019 Breast Cancer Results into Clinical Practice**  
**LISA CAREY**, USA
- 
- 09:40 - 10:00 **Making new technologies relevant to clinicians in 2020**  
**CHARLES PEROU**, USA

10:00 - 10:20 Coffee Break and Poster Viewing

### SESSION 2: Controversies

Chairpersons: **KILEY LOH**, Singapore / **CHANG CHING WAN**, Singapore

- 10:20 - 10:40 **Debate - Should all ER-pos patients receive 10 years of endocrine therapy?**  
 YES: **ELAINE LIM**, Singapore / NO: **ERIC WINER**, USA
- 
- 10:40 - 10:55 **Do all women < 40 require ovarian suppression?**  
**LEE SOO CHIN**, Singapore
- 
- 10:55 - 11:10 **Is there a role for SLN biopsy after neoadjuvant therapy?**  
**HENRY CAIN**, UK
- 
- 11:10 - 11:30 Q and A

### SESSION 3: Early Breast Cancer

Chairperson: **WONG FUH YONG**, Singapore

- 11:30 - 11:50 **Optimizing adjuvant radiation therapy in breast cancer**  
**PHILIP POORTMANS**, France
- 
- 11:50 - 12:50 **Young Women Early Breast Cancer Rapid Fire Tumor Board**  
 Chairpersons: **SHAHEENAH DAWOOD**, UAE / **VERONIQUE TAN**, Singapore  
 Panel: **ERIC WINER**, USA / **JANICE TSANG**, Hong Kong / **LISA CAREY**, USA / **PHILIP POORTMANS**, France  
**SUNG-BAE KIM**, South Korea / **YAP YOON SIM**, Singapore
- 
- 13:00 - 14:00 **Lunch Symposium Sponsored by AstraZeneca**
- 
- 13:00 - 13:30 **Optimizing Endocrine Therapies in the era of CDK4/6i**  
**ERIC WINER**, USA
- 
- 13:30 - 14:00 **Case studies**  
 Moderator: **TBA**  
 Panel: **ERIC WINER**, USA / **TBA**

### SESSION 4: Neoadjuvant/Adjuvant Therapy

Chairpersons: **KARMEN WONG**, Singapore / **YEN-SHEN LU**, Taiwan

- 14:00 - 14:20 **Rationale choices of HER-2 directed therapy in early breast cancer?**  
**SHAHEENAH DAWOOD**, UAE
- 
- 14:20 - 14:40 **What is standard systemic therapy in neoadjuvant therapy in TNBC?**  
**SUDEEP GUPTA**, India
- 
- 14:40 - 15:00 Q and A
- 
- 15:00 - 15:20 Coffee Break

### SESSION 5: Global Tumor Board

Chairpersons: **HOPE RUGO**, USA / **SAMUEL OW**, Singapore

- 15:30 - 16:30 Panel: **AVA KWONG**, Hong Kong / **AZRIF MOHAMMED**, Malaysia / **GIUSEPPE CURIGLIANO**, Italy  
**MASAKAZU TOI**, Japan / **PHILIP POORTMANS**, France / **SUDEEP GUPTA**, India  
**THITIYA SIRISINHA DEJTHEVAPORN**, Thailand / **WONG NAN SOON**, Singapore
- 
- 16:30 - 17:30 **Satellite Symposium Sponsored by Lilly**  
 CDK4/6 inhibitors: Setting new standards for the management of HR+ HER2- Advanced Breast Cancer  
 Chairperson: **YAP YOON SIM**, Singapore  
 Panel: **GIUSEPPE CURIGLIANO**, Italy / **TBA**

apbcs.org

## Translating Evidence into Practice

**DAY 2** (Sunday, 15<sup>th</sup> March 2020)

08:00 - 09:00	Breakfast and Satellite Symposium Sponsored by Pfizer <b>LISA CAREY, USA / TBA</b>
08:00 - 08:05	Introduction of the Session & Speaker <b>YOON SIN YAP, Singapore</b>
08:05 - 08:30	Changing the trajectory of ER+ HER2- mBC : Clinical & Real World Outcomes <b>LISA CAREY, USA</b>
08:30 - 08:45	Panel Discussion Moderator: <b>JANICE TSANG, Hong Kong</b> Panel: <b>LISA CAREY, USA / NAPA PARINYANITIKUL, Thailand / BOMAN DHABHAR, India</b> <b>MASTURA MD YUSOF, Malaysia / TBA</b>
<b>PLENARY SESSION 6: Interrogating the Immune system in Breast Cancer</b> Chairpersons: <b>TEAH BIN TEAN, Singapore / PETER SCHMID, UK</b>	
09:00 - 09:20	Next generation technologies to discern sensitivity to immune checkpoint inhibition <b>CHARLES PEROU, USA</b>
09:20 - 09:40	<b>Debate</b> - Should all TNBC metastatic breast cancer patients who are PD-L1 + receive immune checkpoint inhibitors? YES: <b>LISA CAREY, USA / NO: GIUSEPPE CURIGLIANO, Italy</b>
09:40 - 10:00	Breast Cancer 2025 according to Eric <b>ERIC WINER, USA</b>
10:00 - 10:20	Coffee Break and Poster Viewing
<b>SESSION 7: Unique Clinical Scenarios in Metastatic Breast Cancer</b> Chairpersons: <b>FAYE LIM, Singapore / VIROTE SRIURANPONG, Thailand</b>	
10:20 - 10:35	Novel Approaches to Oligometastatic Disease <b>PHILIP POORTMANS, France</b>
10:35 - 10:50	Systemic Therapy in CNS metastases <b>YAP YOON SIM, Singapore</b>
10:50 - 11:05	Unravelling the complexity of DNA Repair Strategies <b>TIRA TAN, Singapore</b>
11:05 - 11:20	Access to care in the real world in Asia? <b>CHENG-HAR YIP, Malaysia</b>
11:20 - 12:20	Molecular Tumor Board Chairpersons: <b>GIUSEPPE CURIGLIANO, Italy / SUDEEP GUPTA, India</b> Panel: <b>PETER SCHMID, UK / SEOCK-AH IM, Korea / TIRA TAN, Singapore / SHAHEENAH DAWOOD, UAE</b> <b>YEN-SHEN LU, Taiwan / JOLINE LIM, Singapore / SEE HUI TI, Singapore</b>
12:45 - 13:45	Lunch Symposium Supported by MSD
12:45 - 12:50	Welcome and Introduction <b>TBA</b>
12:50 - 13:30	Advances of Immunotherapy in Neoadjuvant TNBC (Triple Negative Breast Cancer) Case studies sharing <b>PETER SCHMID, UK</b>
13:30 - 13:45	Discussion: Q & A Moderator: <b>TBA</b> Panel: <b>PETER SCHMID, UK / BENITA TAN, Singapore</b>
<b>SESSION 8: Novel Targets</b> Chairpersons: <b>SUNG-BAE KIM, South Korea / MASTURA YUSOF, Malaysia</b>	
13:30 - 13:45	Novel Targets metastatic TNBC <b>PETER SCHMID, UK</b>
13:45 - 14:00	Novel Targets HER-2 positive MBC <b>HOPE RUGO, USA</b>
14:00 - 14:15	Novel Targets ER-positive MBC <b>SEOCK-AH IM, South Korea</b>
14:15 - 14:30	Q and A
14:30 - 15:00	Coffee Break
15:00 - 16:30	"Official Best of SABCS® Review" 2019 Chairperson: <b>WONG NAN SOON, Singapore</b> Panel: <b>TBA</b>
16:30 - 17:30	Satellite Symposium Sponsored by Novartis "Novel Therapies in HR+ HER2- Advance Breast Cancer Treatment Landscape" Chairperson: <b>HOPE RUGO, USA</b> Speaker: <b>GIUSEPPE CURIGLIANO, USA</b>

apbcs.org